OBjECTiVES 1. Describe the proposed mechanism of the interaction between clopidogrel and proton pump inhibitors. 2. Summarize the pharmacologic/pharmacodynamic evidence for the interaction between clopidogrel and proton pump inhibitors. 3. Summarize the clinical evidence for the interaction between clopidogrel and proton pump inhibitors. 4. Describe the food and Drug Administration’s updated wa...

National Use of Proton Pump Inhibitors From2007 to 2011 Proton pump inhibitors (PPIs) are a class of therapeutically equivalent medications when used at equivalent doses.1,2 Despite this, high-cost PPIs continue to be used when lowcost equivalents are available. We sought to estimate the national loss associated with the use of high-cost PPIs over their lower-cost alternatives. Furthermore, we ...

OBJECTIVE To study the effects of proton pump inhibitors in reducing vomiting, gastrointestinal bleeding, and chest infections in institutionalised neurologically impaired children with gastroesophageal reflux. DESIGN Prospective study. SETTING A regional hospital, Hong Kong. PATIENTS Neurologically impaired children with refractory gastroesophageal reflux. MAIN OUTCOME MEASURES Episode...

In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with anothe...

Proton pump inhibitors are the most effective agents for suppressing gastric acidity and are the preferred therapy for many acid-related conditions. While proton pump inhibitors have been accessible in intravenous formulations in several European countries, they have been available only as oral drugs in the United States. In the near future, the proton pump inhibitor pantoprazole is likely to b...

Proton pump inhibitors often are prescribed in combination with clopidogrel to decrease risk of gastrointestinal bleeding after acute coronary syndrome. Clopidogrel is a prodrug that has to be metabolized in the liver to generate the active metabolite. Both medications are metabolized largely by the CYP2C19 enzyme; therefore, concerns exist that a drug-drug interaction during concomitant treatm...

INTRODUCTION Antiplatelet therapy remains one of the cornerstones in the management of non-cardioembolic ischemic stroke. However, a significant percentage of patients have concomitant gastroesophageal reflux or peptic ulcer disease that requires acid-reducing medications, the most powerful and effective being the proton pump inhibitors (PPIs). Antiplatelet efficacy, at least in vivo, and parti...